Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent vs Sequential ChemoRT in NSCLC
NCT01134861Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- Jul 1994
- Primary completion
- Oct 1998
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cisplatin, vinblastine and etoposide in non-small cell lung cancer (NSCLC) (3 arms), sponsored by NRG Oncology. Primary endpoint: Overall Survival. Started Jul 1994; status: completed.
02
Drugs
cisplatinvinblastineetoposide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01134861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01134861.